Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system
{{output}}
Background: Relugolix has been used to treat advanced prostate cancer. This study assessed adverse events (AEs) associated with relugolix from the US Food and Drug Administration Adverse Event Reporting System (FAERS). ... ...
